A Commitment to Research

Physicians and academic researchers at the Center for Liver Disease and Transplantation share a deep commitment to clinical innovation. Many of the Center's studies address hepatitis C, which is the leading indication for transplantation and a major cause of organ failure after transplantation.

NewYork-Presbyterian Hospital investigators have participated in virtually every clinical trial of new hepatitis C drugs which have revolutionized the treatment of this infection and increase the likelihood of cure.

Our research protocols include studies of:

  • Hepatitis B and C therapy, both before and after transplant
  • Immunosuppressive therapy for liver transplantation
  • Techniques for predicting likelihood of organ rejection
  • Advanced organ preservation methods
  • Measures of outcomes in liver disease
  • Liver transplantation without chronic immunosuppression (immune tolerance)
To learn more about our current and upcoming clinical trials, please call 212.305.3839. More about the liver cancer research program is available here.